Finnish Biotech Company TILT Biotherapeutics Reports Positive Results in Phase I Trial
In a recent development, Finnish biotech company TILT Biotherapeutics disclosed encouraging outcomes from a Phase I clinical trial of its oncolytic adenovirus TILT-123, in partnership with Merck & Co's KEYTRUDA, aimed at treating platinum-resistant or refractory ovarian cancer. A cohort of 15 patients participated in the trial, with 64.3% demonstrating disease control. Notably, TILT-123, containing tumour necrosis factor alpha (TNFα) and interleukin-2 (IL-2), displayed potential in triggering T-cell responses in both injected and non-injected tumours. The participants displayed a median progression-free survival (PFS) of 105 days and an overall survival (OS) of 280 days. TILT Biotherapeutics is set to present these findings at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
Key Takeaways
- The Phase I clinical trial of TILT-123 + KEYTRUDA by TILT Biotherapeutics established safety and efficacy in patients with platinum-resistant or refractory ovarian cancer, with 64.3% experiencing disease control.
- Patients demonstrated a median progression-free survival (PFS) of 105 days, and intravenous administration of TILT-123 led to systemic tumour transduction and lymphocyte accumulation at tumour sites, showing potential for impacting tumours without direct injection.
- Tumour transduction was observed in 75% of patients on day eight following systemic delivery of TILT-123.
- TILT Biotherapeutics will present these findings at the ASCO Annual Meeting 2024, highlighting treatment options for resistant or refractory ovarian cancer patients.
Analysis
The success of TILT Biotherapeutics' Phase I trial demonstrates promising advancements in oncolytic virotherapy, providing optimism for effective treatment options in challenging cancer cases.
Did You Know?
- Oncolytic adenovirus (TILT-123), featuring TNFα and IL-2, displayed encouraging results in activating T-cell responses and prolonging survival rates in platinum-resistant or refractory ovarian cancer patients.